A
Anders Lindgren
Researcher at Chalmers University of Technology
Publications - 77
Citations - 9754
Anders Lindgren is an academic researcher from Chalmers University of Technology. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 35, co-authored 77 publications receiving 9484 citations.
Papers
More filters
Journal ArticleDOI
Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
TL;DR: There is a strong and probably causal relation between gastroesophageal reflux and esophageaal adenocarcinoma, and the relation between reflux And gastric cardia is relatively weak.
Journal ArticleDOI
Breast cancer screening with mammography : overview of Swedish randomised trials
Lennarth Nyström,Stig Wall,Lars Erik Rutqvist,Anders Lindgren,M. Lindqvist,S. Rydén,J. Andersson,Nils Bjurstam,Gunnar Fagerberg,Jan Frisell,Laszlo Tabar,Lars-Gunnar Larsson +11 more
TL;DR: There was a consistent risk reduction associated with screening in all studies, although the point estimate of the relative risk for all ages varied non-significantly between 0.68 and 0.84.
Journal ArticleDOI
10-Year Results After Sector Resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: A Randomized Trial
Göran Liljegren,Lars Holmberg,Jonas Bergh,Anders Lindgren,László Tabár,Hans Nordgren,Hans-Olov Adami +6 more
TL;DR: Sector resection plus radiotherapy resulted in an absolute reduction in local recurrence of 16% at 10 years compared with surgery alone, and postoperative radiotherapy was not shown to reduce distant recurrences or improve overall survival.
Journal ArticleDOI
Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins
Elisabete Weiderpass,Hans-Olov Adami,John A. Baron,Cecilia Magnusson,Reinhold Bergström,Anders Lindgren,Nestor Correia,Ingemar Persson +7 more
TL;DR: The risk of developing endometrial cancer is increased after long-term use of estrogens without progestins and with cyclically added progestin use, and Continuously added progESTins may be needed to minimize the endometricrial cancer risk associated with estrogen replacement therapy.
Journal ArticleDOI
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
S Sjogren,Mats Inganäs,Torbjörn Norberg,Anders Lindgren,Hans Nordgren,Lars Holmberg,Jonas Bergh +6 more
TL;DR: Use of a cDNA-based sequencing method to determine the status of the p53 gene in primary breast cancers yielded better prognostic information than IHC performed with the Pab 1801 monoclonal antibody.